An official website of the United States government
NIH Websites Are Changing Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Trial Status: closed to accrual
The purpose of this study is to determine whether relatlimab in combination with
nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma
or melanoma that has spread.
Inclusion Criteria
Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system
Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma
Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses
Exclusion Criteria
Participants must not have active brain metastases or leptomeningeal metastases
Participants must not have uveal melanoma
Participants must not have an active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria could apply
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03470922.
